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ABSTRAK	  
	  
Pengenalan	  dan	  Tujuan:	  	  	  	  
	   Kejadian	  kanser	  tiroid	  differentiated	  telah	  meningkat	  dengan	  ketara	  di	  seluruh	  
dunia.	  Tiyroglobulin	  (Tg)	  serum	  dan	  imbasan	  seluruh	  badan	  selepas	  rawatan	  radioiodin	  
(I-­‐131	  Dx	  WBS)	  adalah	  dua	  jenis	  siasatan	  susulan	  yang	  dijalani	  selepas	  rawatan	  kanser	  
di	   peringkat	   awal	   (pembedahan	   pembuangan	   seluruh	   tiroid	   dan	   pemusnahan	   sisa	  
tiroid	  dengan	  radioiodin).	  Kajian	  ini	  bertujuan	  untuk	  menilai	  korelasi	  dan	  nilai	  ramalan	  
Tg	   terangsang	   (sTg)	  6	  bulan	  selepas	  pemusnahan	  sisa	   tiroid	  dengan	   radioiodin	  untuk	  
menentukan	   kewujudan	   penyakit	   berstruktur	   (SED)	   dalam	   I-­‐131	   Dx	   WBS.	   Jika	   sTg	  
mempunyai	   nilai	   ramalan	   yang	   sangat	   tinggi	   terhadap	   kewujudan	   penyakit,	   ia	   boleh	  
menggantikan	  I-­‐131	  Dx	  WBS	  untuk	  menilai	  kewujudan	  penyakit.	  Nilai	  ulangan	  sTg	  juga	  
ditentukan	  bagi	  dua	  sampel	  berlainan	  yang	  diambil	  selepas	  tempoh	  6	  bulan.	  
	  
Metodologi:	  	  	  	  
	   sTg	   diambil	   6	   bulan	   selepas	   rawatan	   peringkat	   awal	   diikuti	   dengan	   I-­‐131	   Dx	  
WBS	  pada	  masa	  yang	  sama.	  Korelasi,	  sensitiviti,	  spesifisiti,	  nilai	  ramalan	  negatif	  (NPV)	  
dan	  nilai	  ramalan	  positif	  (PPV)	  sTg	  terhadap	  SED	  dalam	  I-­‐131	  Dx	  WBS	  ditentukan.	  Enam	  
bulan	  kemudian,	  sTg	  diukur	  semula	  dengan	  menggunakan	  kit	  immunoassay	  ELISA	  yang	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Keputusan:	  
	   sTg	   berkorelasi	   baik	   dengan	   SED	   dalam	   131-­‐I	   Dx	   WBS.	   Kedua-­‐dua	   nilai	  
potongan	  positif	  sTg	  1.0	  ug/L	  dan	  2.0	  ug/L	  mempunyai	  NPV	  yang	  baik	  iaitu	  85.0%	  dan	  
85.7%	  masing-­‐masing	   untuk	   pengecualian	   penyakit.	  Walaubagaimanapun,	   keputusan	  
menunjukkan	   PPV	   adalah	   rendah	   apabila	  menggunakan	   tahap	   potongan	   positif	   10.0	  
ug/L	  iaitu	  	  41.7%	  untuk	  meramalkan	  kewujudan	  penyakit.	  Koefisien	  korelasi	  intraclass	  
adalah	  setinggi	  96.6%	  untuk	  dua	  sTg	  yang	  diambil	  dalam	  tempoh	  6	  bulan	  berbeza.	  	  
	  
Kesimpulan:	  	  	  	  
	   Pengukuran	   sTg	   yang	   dilakukan	   di	   pusat	   kajian	   ini	   boleh	   dipercayai.	   sTg	  
mempunyai	   nilai	   ramalan	   negatif	   yang	   baik	   untuk	   penyakit	   berstruktur,	   dengan	   ini	  
boleh	  melengkapkan	  I-­‐131	  Dx	  WBS	  untuk	  menggecualikan	  kewujudan	  penyakit,	  tetapi	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ABSTRACT	  
Background	  and	  Aims:	  	  	  	   	  
	   The	  incidence	  of	  differentiated	  thyroid	  cancer	  (DTC)	  has	  increased	  substantially	  
worldwide	   in	   the	   past	   four	   decades.	   Serum	   thyroglobulin	   (Tg)	   and	   radioiodine	  
diagnostic	   whole	   body	   scan	   (131-­‐I	   Dx	   WBS)	   are	   two	   main	   surveillance	   tools	   to	  
investigate	  for	  persistent	  disease	  after	  initial	  therapy	  -­‐	  total	  thyroidectomy	  followed	  by	  
radioiodine	   remnant	   ablation	   (RRA).	   This	   study	   evaluates	   the	   correlation,	   predictive	  
value	   and	   reliability	   of	   stimulated	   thyroglobulin	   (sTg)	   for	   detection	   of	   structural	  
evidence	  of	  disease	  (SED)	  in	  131-­‐I	  Dx	  WBS	  6	  months	  after	  initial	  therapy	  in	  the	  Nuclear	  
Medicine	  Department	  Penang	  Hospital	  (NMDPH).	  
	  
Methodology:	  	  	  	  	   	   	  
	   sTg	  was	  measured	  6	  months	  after	  initial	  therapy	  with	  131-­‐I	  Dx	  WBS	  done	  in	  the	  
same	   setting	   to	   evaluate	   SED.	   Correlation,	   sensitivity,	   specificity,	   negative	   predictive	  
value	  (NPV)	  and	  positive	  predictive	  value	  (PPV)	  of	  sTg	  to	  diagnose	  SED	  in	  131-­‐I	  Dx	  WBS	  
was	   analyzed.	   Six	   months	   later,	   repeatability	   of	   sTg	   are	   measured	   under	   similar	  
condition	  using	  the	  similar	  immunoassay	  ELISA	  method	  to	  determine	  the	  reliability	  of	  





	   xi	  
	  
Results:	  	  	  	   	   	   	  
	   sTg	  level	  correlates	  well	  with	  SED	  in	  131-­‐I	  Dx	  WBS.	  Both	  sTg	  cutoff	  positivity	  of	  
1.0	  ug/L	  and	  2.0	  ug/L	  have	  good	  NPV	  of	  85.0%	  and	  85.7%	  respectively	  to	  exclude	  SED	  
in	  I-­‐131	  Dx	  WBS.	  However,	  sTg	  positive	  cutoff	  level	  of	  10.0	  ug/L	  has	  poor	  PPV	  of	  41.7%	  
to	  predict	  the	  presence	  of	  structural	  disease	  in	  I-­‐131	  Dx	  WBS.	  The	  intraclass	  correlation	  
coefficient	  for	  two	  different	  sTg	  taken	  6	  months	  apart	  is	  96.6%.	  
	  
Conclusion:	  	  	   	  	   	   	  
	   sTg	  measurement	  done	  in	  NMDPH	  is	  reliable	  and	  it	  correlates	  well	  with	  SED	  in	  
131-­‐I	  Dx	  WBS.	  sTg	  have	  good	  negative	  predictive	  value	  for	  persistent	  structural	  disease	  
and	  could	  complement	  I-­‐131	  Dx	  WBS	  to	  exclude	  the	  presence	  of	  disease	  but	   is	  not	  a	  




































1.1	   DIFFERENTIATED	  THYROID	  CANCER	  
	   Differentiated	  thyroid	  cancer	  (DTC)	   is	   the	  most	  common	  endocrine	  malignancy.	  
(Lebastchi	  and	  Callender,	  2014).	   It	   is	  mostly	  diagnosed	  at	  young	  age	  with	  more	   than	  
60%	  of	  patients	  are	  below	  55	  years	  old	  when	  diagnosed	  with	  DTC	  (Davies	  and	  Welch,	  
2006).	  DTC	  has	  substantially	  increased	  in	  incidence	  worldwide	  in	  the	  past	  four	  decades	  
and	   is	   mainly	   due	   to	   advancement	   of	   medical	   imaging	   techniques	   to	   detect	   small	  
thyroid	  nodules	  (Chen	  et	  al.,	  2009;	  Colonna	  et	  al.,	  2015;	  Sierra	  et	  al.,	  2016).	  Most	  DTC	  
is	  diagnosed	  with	  only	   locoregional	  disease	  on	  presentation	  which	  carries	  a	  very	   low	  
mortality	  rate	  and	  good	  prognosis	  with	  90-­‐95%	  of	  10	  years	  progression	  free	  survival.	  
Increase	  in	  incidence	  and	  low	  mortality	  rate	  lead	  to	  exponential	  increase	  in	  prevalence	  
of	   DTC	   and	   this	   renders	   long-­‐term	   surveillance	   the	  major	   part	   of	   DTC	  management	  
(Degroot	  et	  al.,	  1990).	  	  
	   Other	   than	   uncommon	   familial	   syndromes	   such	   as	   familial	   adenomatous	  
polyposis,	  Gardner's	   syndrome	  and	  Cowden's	  disease,	   radiation	  exposure	   is	  a	  known	  
predisposing	   factor	   of	   DTC	   (Machens	   et	   al.,	   2002).	   Those	   with	   serum	   thyroid	  
stimulating	  hormone	  (TSH)	  concentration	  above	  the	  mean,	  even	  within	  normal	  range,	  
also	   found	   greater	   likelihood	   to	   develop	   DTC	   than	   populations	   with	   TSH	   below	   the	  
mean	  (Haymart	  et	  al.,	  2008).	  Currently,	  there	  are	  theories	  on	  various	  oncogenes	  and	  
tumor	  suppressor	  gene	  like	  RET,	  ras,	  braf,	  trk,	  met	  and	  P53	  playing	  roles	  in	  the	  signal	  
transduction	  systems	  related	  to	  the	  development	  of	  thyroid	  cancer	  (Parameswaran	  et	  
al.,	   2010).	   The	   most	   observed	   genetic	   alteration	   in	   papillary	   thyroid	   cancer	   is	  






and	  prognostication	  of	  papillary	   thyroid	  cancer.	  However,	   its	  clinical	   relevance	   is	   still	  
unclear	  (Baldini	  et	  al.,	  2014).	  	  
	   DTC	   consists	   mainly	   of	   papillary	   thyroid	   carcinoma	   (83%),	   follicular	   thyroid	  
carcinoma	   (15%)	   and	   Hurthle	   cell	   carcinoma	   (2%)	   (Sipos	   and	   Mazzaferri,	   2010).	  
Papillary,	  follicular	  and	  Hurthle	  cell	  thyroid	  cancer	  vary	  in	  histological	  appearance	  but	  
there	   is	   no	   difference	   in	   functionality	   of	   iodine	   uptake	   (Baldini	   et	   al.,	   2014).	   This	  
enables	  radioiodine	  to	  be	  an	  widely	  utilized	  therapeutic	  and	  diagnostic	  agent	  for	  DTC	  
patients.	  	  
	  
1.2	   RISK	  STRATIFICATION	  AND	  MANAGEMENT	  OF	  DIFFERENTIATED	  THYROID	  
	   CANCER	  
The	  management	  plan	  of	  DTC	  depends	  very	  much	  on	  the	  risk	  of	  recurrence	  in	  
10	   years	   time.	   The	   American	   Joint	   Committee	   on	   Cancer	  (AJCC)	   on	  tumor-­‐node-­‐
metastasis	   (TNM)	   cancer	   staging	   system	   emphasizes	   a	   few	   high	   risk	   factors	   for	  
persistent/	  recurrent	  disease	  in	  DTC.	  Age	  at	  the	  time	  of	  diagnosis,	  tumor	  size,	  high-­‐risk	  
histology,	   extent	   of	   tumor,	   vascular	   invasion,	   cervical	   lymph	  nodes	   involvement	   and	  
distant	  metastasis	  are	  associated	  with	  higher	   risk	  of	  DTC	   (Edge	  and	  Compton,	  2010).	  
Patients	  diagnosed	  with	  DTC	  at	  age	  above	  45	  or	  below	  10	  years	  old	  carry	  higher	  risk	  of	  
recurrence.	  A	   recent	   large	   scale	   study	   involving	  9484	  patients	   suggests	  using	   age	  55	  
and	  above,	  instead	  of	  45,	  as	  the	  cutoff	  age	  to	  differentiate	  between	  high	  and	  low	  risk	  
age	   groups.	   This	   has	   downstaged	   12%	  of	   patients	   from	   the	   high	   risk	   to	   the	   low	   risk	  






(Nixon	  et	  al.,	  2016).	  	  
High	   risk	   histological	   findings	   (tall	   cell	   or	   columnar	   cell	   in	   papillary	   thyroid	  
carcinoma,	   widely	   invasive	   follicular	   thyroid	   carcinoma,	   poorly	   differentiated	   and	  
Hurthle	  cell	  carcinomas)	  are	  associated	  with	  a	  poorer	  outcome	  (Degroot	  et	  al.,	  1990;	  
Asanuma	   et	   al.,	   2001).	   The	   extent	   of	   the	   tumor	   also	   affects	   the	   risk	   of	   developing	  
recurrent	   disease.	  Gross	   extrathyroidal	   extension	   of	   tumor	   into	   adjacent	   soft	   tissue,	  
incomplete	   tumor	   resection,	   >5	   metastatic	   lymph	   nodes	   or	   any	   lymph	   nodes	  
metastasis	   >3	   cm,	  extensive	   vascular	   invasion	   in	   follicular	   thyroid	   cancer	  and	  distant	  
metastasis	   are	   among	   the	   high	   risk	   features	   stated	   in	   American	   Thyroid	   Association	  
guidelines	  2015.	  Other	  than	  these	  mentioned	  features,	  patients	  are	  categorized	  to	  low	  
and	  intermediate	  risk	  groups	  (Refer	  Appendix	  A).	  
The	  fundamental	  management	  approach	  for	  all	  DTC	  includes	  surgical	  resection,	  
with	   or	   without	   radioiodine	   remnant	   ablation	   (RRA),	   followed	   by	   long	   term	   thyroid	  
stimulating	   hormone	   (TSH)	   suppressions	   therapy	   with	   oral	   L-­‐Thyroxine.	   Types	   of	  
surgical	   resection,	   either	   lobectomy	   or	   total	   thyroidectomy,	   with	   or	   without	  
prophylactic	  central	  compartment	  neck	  dissection,	  depends	  on	  the	  size	  of	  the	  primary	  
tumor,	   intra-­‐operative	   findings	   and	   histological	   findings	   (Beenken	   et	   al.,	   2000).	   The	  
surgical	   approach	   of	   DTC	  with	   tumor	   size	   larger	   than	   1.0	   cm	   is	   total	   thyroidectomy	  
with	   optional	   RRA	   (Chow	   et	   al.,	   2003;	   Moo	   and	   Fahey	   III,	   2011).	   Subsequently,	  
radioiodine-­‐131	  post	  therapy	  whole	  body	  scan	  (131-­‐I	  Rx	  WBS)	  day	  4-­‐7	  post	  RRA	  will	  be	  
performed	  for	  restaging	  (Pacini	  et	  al.,	  2010;	  National	  Comprehensive	  Cancer	  Network,	  






follicular	  thyroid	  cancer	  are	  considered	  to	  be	  in	  low	  risk	  group,	  lobectomy	  without	  RRA	  
is	   recommended.	   However,	   features	   of	   multifocality	   and	   cervical	   lymph	   nodes	  
metastasis	  carry	  higher	  risk	  of	  persistent/	  recurrent	  disease	  and	  similar	  initial	  therapy	  
regime	  (total	  thyroidectomy	  followed	  by	  RRA)	  would	  be	  adopted	  (Chow	  et	  al.,	  2003).	  
Recent	  large	  prospective	  cohort	  studies	  on	  risk	  stratification	  done	  6-­‐12	  months	  
after	  initial	  therapy,	  based	  on	  therapy	  response,	  is	  superior	  to	  previously	  adopted	  risk	  
stratification	  done	  during	  initial	  therapy.	  The	  attempt	  to	  re-­‐stratify	  patients	  based	  on	  
response	   to	   initial	   therapy	   helps	   prevent	   over-­‐treatment	   of	   patients	   with	   low-­‐risk	  
disease	   while	   providing	   a	  more	   comprehensive	   approach	   to	   those	   remaining	   in	   the	  
high	  risk	  group	  (Castagna	  et	  al.,	  2011;	  Tuttle	  and	  Sabra,	  2013).	  	  	  
The	   latest	   American	   Thyroid	   Association	   guideline	   2015	   has	   categorized	   the	  
response	   to	   initial	   therapy	   into	   four	   groups:	   excellent	   response,	   biochemical	  
incomplete	   response,	   structural	   incomplete	   response	   and	   indeterminate	   response	  
(Table	  1).	  Response	  assessment	  shall	  be	  done	  within	  2	  years	  after	  initial	  therapy.	  The	  
subsequent	  management	  approach	  for	  different	  groups	  of	  patients	  differs	  according	  to	  
the	   risk	   of	   recurrent	   disease	   in	   future	   and	   disease	   specific	   death.	   It	   is	   stated	   that	  
patients	   who	   achieves	   excellent	   response	   to	   initial	   therapy	   (in	   both	   structural	   and	  
biochemical	   remission)	  have	  only	  1%	  to	  4%	  disease	  specific	  death	  rate.	  On	  the	  other	  
hand,	   patients	   who	   have	   persistent	   locoregional	   structural	   disease	   have	   disease	  
specific	  death	  rate	  of	  11%	  while	  distant	  metastasis	  carries	  up	  to	  50%	  of	  disease	  specific	  
death	   rate	   (Haugen	   et	   al.,	   2016).	   As	   such,	   the	   treating	   physician	   must	   attempt	   to	  






and	   structural	   imaging	   after	   initial	   therapy	   due	   to	   clinical	   implications	   as	   shown	   in	  
Table	  1	  below.	  
	  
	  
Table	  1	  	   Clinical	   Implications	   of	   Response	   to	   Therapy	   Reclassification	   in	  
	   	   	   Patients	  with	   Differentiated	   Thyroid	   Cancer	   Treated	  with	   Total	  
	   	   	   Thyroidectomy	  and	  Radioiodine	  Remnant	  Ablation,	  	  










1.3	   IMAGING	  MODALITY	  IN	  DIFFERENTIATED	  THYROID	  CANCER	  FOLLOW	  UP	  
Radioiodine-­‐131	   diagnosis	   whole	   body	   scan	   (I-­‐131	   Dx	   WBS)	   has	   been	   a	  
procedure	   of	   choice	   since	   a	   few	   decades	   ago	   to	   determine	   persistent/	   recurrent	  
disease	  in	  the	  first	  2	  years	  after	  initial	  therapy	  for	  ATA	  low	  and	  intermediate	  risk	  group	  
patients.	  DTC	  preserves	  functional	  integrity	  of	  sodium	  iodide	  symporter,	  	  thus	  able	  to	  
concentrate	   iodide,	   enabling	   I-­‐131	   Dx	   WBS	   to	   be	   an	   useful	   tool	   to	   detect	  
micrometastasis	   and	   macrometastasis	   disease	   (Galligan	   et	   al.,	   1982;	   Van	   Sorge-­‐Van	  
Boxtel	  et	  al.,	  1993).	  	  
	   British	  Thyroid	  Association	  guideline	   recommends	   the	  use	  of	  ultrasound	  neck	  
and	  serum	  Tg	  in	  the	  follow	  up	  of	  low	  risk	  DTC	  patients	  (Perros	  et	  al.,	  2014).	  One	  study	  
suggests	  that	  when	  sTg	  <3	  ug/L,	  I-­‐131	  Dx	  WBS	  may	  be	  avoided	  in	  the	  follow-­‐up	  of	  DTC	  
patients	   and	   only	   neck	   ultrasound	   is	   warranted	   to	   monitor	   persistent/	   recurrent	  
disease	  (Pacini	  et	  al.,	  2002).	  Nevertheless,	  ultrasound	  neck	  has	  limitation	  to	  pin	  point	  
micrometastasis	   or	   lesion	   smaller	   than	   2	   mm	   and	   is	   not	   suitable	   to	   visualize	   deep	  
cervical	  or	  mediastinal	   regions.	  Thus	  most	  centers	  are	  still	  adopting	   I-­‐131	  Dx	  WBS	  as	  
the	  main	  modality	  for	  assessment	  of	  structural	  disease.(Lee	  et	  al.,	  2013).	  	  
For	   high	   risk	   patients,	   computed	   tomographic	   (CT),	   magnetic	   resonance	  
imaging	   	   (MRI)	   or	   18-­‐fluorodeoxyglucose	   positron	   emission	   tomography/computed	  
tomography	  (18F-­‐FDG	  PET/CT)	  are	  the	  modalities	  of	  choice	  for	  further	  investigation	  for	  
metastatic	   disease,	   depending	   on	   the	   clinical	   presentation	   (Lamartina	   et	   al.,	   2016).	  
Suspicious	  of	  non-­‐iodine	  avid	  disease	  should	  be	  raised	  in	  cases	  of	  elevation	  and	  rising	  






18F-­‐FDG	   PET/CT	   proved	   to	   be	   a	   useful	   diagnostic	   tool	   to	   detect	   and	   localize	  
locoregional	  recurrences	  as	  well	  as	  distant	  metastases	  in	  non-­‐iodine	  avid	  disease	  (Kim	  
et	  al.,	  2009;	  Dennis	  et	  al.,	  2012;	  Hamed	  et	  al.,	  2014).	  High	  18F-­‐FDG	  PET/CT	  uptake	  in	  
non-­‐iodine	   avid	   lesions	   suggests	   lost	   of	   sodium-­‐iodide	   symporter	   activity	   and	  
aggressive	   cell	   growth	   with	   enhanced	   glucose	   transporter	   genes	   expression	   in	   DTC	  
(Dong	  et	  al.,	  2009).	  	  
However,	   interestingly	   in	   some	   cases	   of	   raised	   serum	   Tg	   levels	   but	   negative	  
findings	  in	  both	  I-­‐131	  Dx	  WBS	  and	  18F-­‐FDG	  PET/CT,	  good	  evolution	  is	  noted	  on	  follow-­‐
up	   serum	   Tg	   with	   descending	   Tg	   trend	   despite	   without	   additional	   treatment.	   A	  
significant	  percentage	  of	  them	  even	  reach	  normal	  Tg	  levels	  on	  follow-­‐up.	  As	  such,	  the	  
predictive	   values	   of	   sTg	   for	   persistent/	   recurrent	   disease	   and	   the	   optimum	   positive	  
cutoff	  level	  of	  sTg	  to	  predict	  persistent/	  recurrent	  disease	  is	  essential	  to	  avoid	  over-­‐	  or	  
under-­‐	   investigation	   into	   this	   group	  of	  patients	  with	   raised	   serum	  Tg	  and	  negative	   I-­‐
131	  Dx	  WBS	  (Pachon-­‐Garrudo	  et	  al.,	  2012).	  
	  
1.4	   THYROGLOBULIN	  IN	  DIFFERENTIATED	  THYROID	  CANCER	  FOLLOW-­‐UP	  
	   Tg	   is	   a	   thyroid	   specific	   glycoprotein	   produced	   in	   thyroid	   follicular	   cells	  
prompted	   by	   TSH	   stimulation.	   Tg	   stays	   mainly	   intrathyroidal	   under	   normal	  
physiological	   conditions	   and	   acts	   as	   the	   precursor	   of	   thyroid	   hormone	   synthesis.	   A	  
small	  proportion	  is	  iodized	  as	  active	  thyroid	  hormone	  and	  released	  into	  the	  circulation	  
through	   the	   process	   of	   exocytosis	   (Shlossberg	   et	   al.,	   1979;	   Rivolta	   and	   Targovnik,	  






in	  DTC	   (Evans	   et	  al.,	   2015).	   Tg	   taken	  under	  TSH	   stimulation,	  either	  by	  withdrawal	  of	  
thyroxine	   or	   human	   recombinant	   TSH,	   is	   called	   stimulated	   Tg	   (sTg).	   Serum	   TSH	   >30	  
mU/L	  is	  essential	  not	  only	  for	  adequate	  activation	  of	  thyroid	  follicular	  cells	  to	  take	  up	  
radioiodine	  but	  also	  to	  ensure	  the	  synthesis	  and	  release	  of	  serum	  Tg	  which	  improves	  
the	  detectability	  of	  serum	  Tg	  (Duntas	  and	  Biondi,	  2007).	  
	   1.0	  ug/L	  serum	  Tg	  concentration	  indicates	  presence	  of	  approximately	  one	  gram	  
of	   normal	   thyroid	   tissue	   in	   the	   body.	   Post	   total	   thyroidectomy	   and	   successful	   RRA,	  
when	   there	   is	   no	   more	   thyroid	   tissue	   left	   in	   the	   body,	   serum	   Tg	   should	   be	  
undetectable	   (Francis	   and	   Schlumberger,	   2008).	   Thus,	   in	   DTC	   patients	   after	   initial	  
therapy,	   serum	   Tg	   taken	   at	   least	   3	  months	   after	   completion	   of	   therapy,	   becomes	   a	  
very	   useful	   marker	   to	   exclude	   persistent	   disease	   (Schlumberger	   and	   Baudin,	   1998).	  
Any	   patient	   post	   total	   thyroidectomy	   and	   RRA	   with	   detectable	   serum	   Tg	   must	   be	  
regarded	   as	   having	   persistent	   disease	   and	   subsequent	   work-­‐up	   to	   localize	   Tg	  
producing	   lesion	   is	   required	   (Pacini	  and	  Pinchera,	  1999).	  A	  pooled	  data	   from	  a	  meta	  
analysis	  demonstrated	  sTg	  taken	  within	  2	  years	  after	  initial	  therapy	  had	  NPV	  of	  97%	  for	  
persistent/	  recurrent	  disease	  when	  using	  positive	  cutoff	   level	  of	  1.0	  ug/L	  while	  cutoff	  
level	  of	  2.0	  ug/L	  achieved	  NPV	  of	  99%	  (Giovanella	  et	  al.,	  2013).	  On	  top	  of	  diagnostic	  
value,	  sTg	   level	  post	   initial	  therapy	  also	  has	  prognostic	  significance	  with	  higher	   levels	  
implying	  higher	  risk	  of	  future	  cancer	  recurrence	  (Pelttari	  et	  al.,	  2010).	  	  
	   A	   few	   studies	   established	   positive	   relationship	   between	   serum	   Tg	  
concentration	   and	   tumor	   burden	   but	   the	   exact	   amount	   of	   cancer	   cells	   required	   to	  






thyroid	  tissue	  present,	  the	  degree	  of	  TSH	  receptor	  stimulation	  and	  the	  tumor's	  intrinsic	  
ability	   to	   synthesize	  and	  secrete	  Tg	   (Spencer	   et	  al.,	  1999).	   In	  DTC	  patients	  post	   total	  
thyroidectomy	   without	   RRA,	   sTg	   has	   excellent	   correlation	   with	   distant	   metastases	  
(Ashcraft	  and	  Van	  Herle,	  1981;	  Ramanna	  et	  al.,	  1985).	  On	  the	  contrary,	  for	  those	  post	  
total	  thyroidectomy	  and	  RRA	  patients,	  the	  detection	  rates	  of	  remnant	  or	  residual	  DTC	  
tissue	  are	  80%	  when	  sTg	  ≥10	  ug/L,	  97%	  with	  sTg	  ≥5	  ug/L	  and	  100%	  with	  sTg	  ≥2	  ug/L	  
(Fatourechi	  and	  Hay,	  2000).	  An	  observational	  study	  of	  366	  DTC	  patients	  found	  that	  sTg	  
obtained	  6	  months	  after	   initial	   therapy,	  using	  positive	  cutoff	   level	  of	  10.0	  ug/L	  has	  a	  
sensitivity	  of	  100.0%,	  specificity	  of	  93.1%	  and	  positive	  predictive	  value	  (PPV)	  of	  77%	  for	  
recurrent	  disease,	  while	  sTg	  positive	  cutoff	  level	  of	  2.0	  ug/L	  has	  similar	  sensitivity	  but	  
lower	   specificity	   (82%)	   and	   low	   PPV	   (54%)	   for	   recurrent	   disease.	   (Heemstra	   et	   al.,	  
2007a).	  
Unfortunately,	  anti-­‐Tg	  antibody	  (anti-­‐Tg	  Ab)	   interference	  could	  alter	  serum	  Tg	  
concentration	  in	  the	  samples	  causing	  falsely	  low	  negative	  serum	  Tg.	  This	  happens	  in	  up	  
to	   20%	   of	   DTC	   patients	   (Pacini	   and	   Pinchera,	   1999).	   All	   available	   immunoassays	   to	  
measure	   Tg	   have	   similar	   limitations	   and	   in	   the	   presence	   of	   anti-­‐Tg	   Ab	   it	   becomes	  
technically	   challenging	   to	   ensure	   the	   accuracy	   of	   serum	   Tg	  measurement	   (Tate	   and	  
Ward,	  2004).	  Thus,	  Tg	  is	  only	  valid	  as	  a	  diagnostic	  or	  surveillance	  tool	  in	  the	  absence	  of	  
anti-­‐Tg	   Ab.	   sTg	  measurements	   from	   the	   washout	   of	   the	   needle	   used	   in	   fine-­‐needle	  
aspiration	  cytology	   in	  metastatic	   lymph	  nodes	  are	  not	  affected	  by	   circulating	  anti-­‐Tg	  
Ab	  and	  overcomes	  the	  pitfall	  to	  correctly	  diagnose	  early	  DTC	  recurrence.	  However,	  this	  






For	   the	   reasons	   mentioned	   above,	   the	   latest	   American	   Thyroid	   Association	  
guideline	   (2015)	   emphasizes	   the	   role	   of	   Tg	   in	   the	   follow-­‐up	   of	   patients	   after	   initial	  
therapy	   in	  DTC.	   The	   Tg	   level	   has	   significant	   impact	   on	   the	  management	   of	   patients,	  
especially	  those	  who	  have	  no	  SED	  in	  imaging	  (Table	  1).	  Patients	  who	  exhibited	  no	  SED	  
in	   imaging	   and	   Tg	   <1	   ug/L	   off	   L-­‐Thyroxine	   or	   Tg	   <0.2	   ug/L	   on	   	   L-­‐Thyroxine	   were	  
considered	   having	   excellent	   response	   to	   therapy	   and	   needing	   less	   degree	   of	   TSH	  
suppression	   and	   less	   intensity	   of	   follow-­‐up.	  On	   the	  other	   hand,	   after	   initial	   therapy,	  
when	  there	  is	  no	  SED,	  sTg	  ≥10.0	  ug/L	  off	  L-­‐Thyroxine	  or	  sTg	  ≥1.0	  ug/L	  on	  L-­‐Thyroxine	  or	  
rising	   trend	   of	   serum	   Tg	   should	   prompt	   additional	   investigations	   and	   potential	  
additional	  therapies	  might	  be	  needed.	  The	  reason	  that	  being	  with	  the	  latter	  mentioned	  
Tg	   level,	   despite	   absence	   of	   SED,	   patients	   have	   20%	   risk	   of	   developing	   structural	  
disease	  later	  (Haugen	  et	  al.,	  2016).	  	  	  
	  
1.5	   MANAGEMENT	  OF	  DIFFERENTIATED	  THYROID	  CANCER	  IN	  MALAYSIA	  
Malaysia	   National	   Cancer	   Registry	   Report	   2007-­‐2011	   showed	   that	   thyroid	  
cancer	  is	  the	  tenth	  commonest	  cancers	  in	  Malaysia	  with	  average	  incidence	  of	  110	  new	  
cases	  in	  male	  and	  345	  new	  cases	  in	  female	  per	  year	  	  (AbM	  et	  al.,	  2016).	  This	  study	  was	  
conducted	   in	  Nuclear	  Medicine	  Department	  Penang	  Hospital,	   the	  third	   largest	  center	  
in	  Malaysia	   offering	   RRA	   for	   DTC	   patients.	  Malaysian	   Consensus	   Guidelines	   on	  Well	  
Differentiated	  Thyroid	  Cancer	  has	  similar	  recommendation	  to	  ATA	  guidelines	  in	  terms	  
of	  surgical	  management,	  RRA,	  TSH	  suppression	  therapy	  and	  follow	  up	  on	  DTC	  patients.	  	  






followed	   by	   RRA	   with	   a	   day	   4-­‐5	   post	   therapy	   whole	   body	   scan	   (I-­‐131	   Rx	  WBS)	   for	  
cancer	  restaging.	  For	  those	  having	  iodine	  uptake	  in	  neck	  only	  and	  not	  elsewhere	  in	  the	  
body,	  a	  radioiodine	  diagnostic	  whole	  body	  scan	  (I-­‐131	  Dx	  WBS)	  will	  be	  done	  6	  months	  
later	   for	   assessment.	   On	   the	   other	   hand,	   for	   patients	   with	   distant	   metastasis,	  
subsequent	  high	  dose	  radioiodine	  therapy	  (RAT)	  will	  be	  employed.	  
As	  mentioned	  earlier,	  131-­‐I	  Dx	  WBS	  was	  the	  imaging	  of	  choice	  to	  assess	  disease	  
status	  6	  months	  after	  initial	  therapy	  for	  DTC	  patients	  in	  Malaysia.	  For	  those	  who	  have	  
achieved	  complete	  structural	  response	  to	  therapy	  (I-­‐131	  Dx	  WBS	  shows	  no	  SED	  in	  the	  
neck	  and	  elsewhere),	  regardless	  of	  sTg	  level,	  a	  second	  131-­‐I	  Dx	  WBS	  will	  be	  repeated	  6	  
months	   later	   as	   confirmatory	   study.	  On	   the	   contrary,	   if	   there	   is	  persistent	   structural	  
disease	  6	  months	  after	  RRA,	  high	  dose	  RAT	  will	  be	  given	  to	  patients.	  Patients	  who	  have	  
two	  consecutive	  I-­‐131	  Dx	  WBS	  showing	  no	  SED	  but	  noted	  raised	  sTg	  and	  the	  trend	  is	  
rising	   with	   few	   consecutive	   readings	   would	   be	   further	   investigated	   with	   18F-­‐FDG	  
PET/CT	  to	  look	  for	  non-­‐iodine	  avid	  disease.	  
Even	  though	  serum	  Tg	  and	  131-­‐I	  Dx	  WBS	  are	  considered	  two	  fundamental	  tools	  
in	  assessing	  DTC	  status	  after	  initial	  therapy	  in	  Malaysia,	  there	  has	  been	  no	  study	  done	  
to	   determine	   the	   correlation	   and	   independent	   predictive	   value	   of	   serum	   Tg	   for	   the	  
presence	  of	  persistent	  SED	  in	  131-­‐I	  Dx	  WBS	  in	  DTC	  patients.	  In	  routine	  clinical	  practice,	  
all	   samples	  are	  sent	   to	  outsource	   laboratory,	   Institute	  of	  Medical	  Research	  Malaysia,	  
for	  measurement.	  The	  reliability	  of	  Tg	  measurement	  used	  would	  be	  of	  great	  concern	  
as	   it	  has	  significant	   impact	   for	   the	  course	   follow-­‐up	  on	  DTC	  patients	   in	  NMDPH.	  This	  

























2.1	  	   OBJECTIVES	  OF	  THE	  STUDY	  
General	  Objective	  
To	  determine	  the	  correlation,	  positive	  predictive	  value	  and	  negative	  predictive	  
value	  of	  sTg	  for	  SED	  in	  I-­‐131	  Dx	  WBS	  6	  months	  after	  RRA.	  
Specific	  Objective	  
To	  determine	  the	  repeatability	  of	  sTg	  in	  the	  same	  patient	  measured	  6	  months	  
apart	  in	  the	  same	  laboratory	  using	  the	  same	  method.	  	  
	  
2.2	   BENEFITS	  OF	  THE	  STUDY	  	  
If	   the	   NPV	   and	   PPV	   of	   sTg	   for	   persistent	   disease	   are	   very	   high,	   it	   may	   be	  
considered	  as	  a	  substitute	  for	  I-­‐131	  Dx	  WBS	  to	  detect	  persistent	  disease.	  
	  
2.3	   STUDY	  HYPOTHESIS	  
1.	   sTg	  positive	  cutoff	  level	  1.0	  ug/L	  and	  2.0	  ug/L	  has	  NPV	  95%	  	  
	   to	  exclude	  SED	  in	  I-­‐131	  Dx	  WBS.	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3.1	  	   STUDY	  BACKGROUND	  
This	  study	  was	  conducted	  among	  ATA	   low	  and	   intermediate	  risk	  DTC	  patients	  
treated	  in	  NMDPH	  for	  the	  duration	  of	  18	  months.	  	  
This	   study	   has	   the	   approval	   of	   Medical	   Research	   and	   Ethics	   Committee,	  
Ministry	   of	   Health	   Malaysia	   with	   reference	   number	   NMRRM–15–1324-­‐25854	  
[Appendix	  L]	  and	  The	  Research	  Ethics	  Committee	  (Human),	  school	  of	  Medical	  Sciences,	  
Universiti	   Sains	   Malaysia	   with	   certificate	   number	   USM/JEPeM/16020051	  	  	  	  	  	  	  	  	  
[Appendix	  M].	  	  
	  
3.2	   SUBJECT	  RECRUITMENT	  
	   All	  eligible	  patients	  aged	  18	  and	  above	  with	  histologically	  proven	  differentiated	  
thyroid	  carcinoma	  who	  came	   for	   I-­‐131	  Dx	  WBS	  6	  months	  after	  RRA	  within	   the	  study	  
period	  in	  NMDPH	  were	  recruited.	  	  
	   The	   eligibility	   criteria	   included	   prior	   total	   thyroidectomy	   followed	   by	  
radioiodine	  remnant	  ablation	  6	  months	  earlier,	  where	  a	  day	  4-­‐5	  post	  I-­‐131	  treatment	  
whole	  body	  scan	  showed	  uptake	  in	  the	  neck	  only	  (those	  with	  locally	  advanced	  cancer	  
or	  distance	  metastasis	  were	  excluded	  from	  the	  study	  as	  they	  were	  given	  high	  dose	  RAT	  
instead	  of	  doing	  a	  I-­‐131	  Dx	  WBS);	  adequate	  TSH	  stimulation	  with	  level	  >30	  mU/L;	  and	  
without	  the	  interference	  of	  	  anti-­‐Tg	  antibody	  in	  the	  serum.	  	  
	   A	   total	   of	   46	   patients	   were	   recruited	   for	   this	   study	   and,	   of	   whom	   4	   were	  
dropped	  from	  the	  study	  due	  to	  inadequate	  TSH	  stimulation	  and	  the	  presence	  of	  anti-­‐






3.3	   STEPS	  AND	  INSTRUMENTS	  OF	  THE	  STUDY	  
Patients	  who	  came	  for	  131-­‐I	  Dx	  WBS	  were	  prepared	  as	  per	  our	  usual	  protocol	  
(withheld	  oral	  L-­‐thyroxine	  for	  4	  weeks	  and	  on	  low	  iodine	  diet	  for	  2	  weeks).	  After	  taking	  
consent,	  medical	  officers	  in	  NMDPH	  took	  the	  relevant	  history	  and	  performed	  physical	  
examination.	   The	   indication	   of	   I-­‐131	   Dx	  WBS	   and	   radiation	   safety	   precautions	  were	  
explained	  to	  patients.	  	  
Venous	  blood	  was	   taken	   for	   serum	  Tg,	   anti-­‐Tg	   antibody,	   T4	   and	   TSH	  prior	   to	  
radioiodine	   administration.	   All	   serum	   Tg	   was	   sent	   to	   Institute	   of	   Medical	   Research	  
(IMR)	  Malaysia	   for	   testing	   using	   the	   ELISA	   kit	   produced	   by	  Dialab.	   All	   serum	   anti-­‐Tg	  
antibody	   was	   taken	   from	   the	   similar	   syringe	   and	   was	   tested.	   Patients	   with	   the	  
presence	  of	  serum	  anti-­‐Tg	  antibody	  were	  later	  excluded	  from	  this	  study.	  
Image	  acquisition	  of	  the	  whole	  body	  was	  performed	  on	  day	  4-­‐5	  post	  5	  mCi	  of	  
radioiodine	   I-­‐131	   administration,	   using	   gamma	   camera	   according	   to	   protocol	   (Refer	  
appendix	   B).	   Scan	   findings	   were	   interpreted	   by	   a	   nuclear	   medicine	   specialist	   in	  
NMDPH.	  	  
The	  subsequent	  serum	  TSH,	  Tg	  and	  anti-­‐Tg	  antibody	  were	  taken	  6	  months	  later	  
(12	  months	  post	  RRA)	  using	  the	  same	  preparation	  protocol.	  Patients	  with	  the	  presence	  










3.4	   STUDY	  TERMINOLOGIES	  
Radioiodine	  Remnant	  Ablation	  (RRA)	  
Destruction	  of	  remnant	  thyroid	  tissue	  or	  microscopic	  disease	  in	  the	  thyroid	  bed	  after	  
total	  or	  near-­‐total	  thyroidectomy	  with	  administration	  of	  80-­‐120	  mCi	  radioiodine-­‐131.	  
Radioiodine	  Therapy	  (RAT)	  
Destruction	   of	   microscopic	   and	   macroscopic	   thyroid	   neoplastic	   cells	   with	  
administration	  of	  100-­‐150	  mCi	  radioiodine-­‐131.	  
Post	  Therapy	  Whole	  Body	  Scan	  (I-­‐131	  Rx	  WBS)	  
Whole	   body	   scan	   with	   gamma	   camera	   after	   4/5	   days	   of	   high	   dose	   radioiodine-­‐131	  
ingestion.	  
Diagnostic	  Whole	  Body	  Scan	  (I-­‐131	  Dx	  WBS)	  
Whole	  body	  scan	  with	  gamma	  camera	  after	  4/5	  days	  of	   low	  dose	  5	  mCi	   radioiodine-­‐
131	  ingestion.	  	  
Structural	  Evidence	  of	  Disease	  (SED)	  
Presence	  of	  normal	  thyroid	  tissue,	  microscopic	  disease	  in	  the	  thyroid	  bed	  or	  metastatic	  
regional	  cervical	  lymph	  nodes	  detected	  by	  imaging.	  
Initial	  therapy	  
Total	   thyroidectomy	   followed	   by	   radioiodine	   remnant	   ablation	   with	   high	   dose	  
radioiodine	  (80	  to	  120	  mCi)	  for	  DTC	  patients.	  
Persistent	  disease	  
Persistent	   normal	   thyroid	   tissue,	   microscopic	   disease	   in	   the	   thyroid	   or	   metastatic	  







The	  return	  of	  thyroid	  cancer	  in	  any	  part	  of	  the	  body	  after	  successful	  treatment.	  
Thyroglobulin	  (Tg)	  
Thyroglobulin	  is	  a	  large,	  iodinated,	  glycosylated	  protein	  with	  a	  molecular	  mass	  of	  660	  
kDa,	  produced	  by	  thyroid	  follicular	  cells.	  Its	  level	  is	  measured	  by	  immunoassay.	  
Unstimulated	  Thyroglobulin	  (sTg)	  
Serum	   thyroglobulin	   level	  measured	  when	   patients	   are	   on	   TSH	   suppression	   therapy	  
with	  Tab	  L-­‐Thyroxine.	  	  
Stimulated	  Thyroglobulin	  (sTg)	  
Serum	   thyroglobulin	   level	   measured	   after	   4	   weeks	   of	   TSH	   suppression	   therapy	  
(Thyroxine)	  withdrawal	  with	  TSH	  level	  of	  >30	  mU/L.	  	  
Sensitivity	  
Sensitivity	  in	  this	  study	  denotes	  the	  ability	  of	  sTg	  to	  detect	  SED	  in	  I-­‐131	  Dx	  WBS.	  	  
Specificity	  
Specificity	  in	  this	  study	  denotes	  the	  ability	  of	  sTg	  to	  exclude	  SED	  in	  I-­‐131	  Dx	  WBS.	  	  
Negative	  Predictive	  Value	  (NPV)	  
The	  probability	  of	  patients	  who	  have	  a	  negative	  sTg	  test	  result	  actually	  having	  no	  SED	  	  
in	  I-­‐131	  Dx	  WBS.	  It	  is	  the	  true	  negative	  rate	  among	  the	  negative	  test	  results.	  
Positive	  Predictive	  Value	  (PPV)	  
The	  probability	  of	  patients	  who	  have	  a	  positive	  sTg	  test	  result	  actually	  is	  having	  SED	  	  







3.5	  	   DATA	  COLLECTION	  AND	  ANALYSIS	  
Main	   demographic	   details	   of	   patients	   such	   as	   age,	   gender,	   histopathological	  
findings	  (size	  of	  tumor,	  papillary	  or	  follicular;	  metastasis	  to	  cervical	  lymph	  nodes)	  were	  
taken.	  Date	  of	  RRA,	  radioiodine	  dose	  administered,	  pre-­‐RRA	  sTg,	  anti-­‐Tg	  antibody,	  T4	  
and	   TSH	   levels	   as	   well	   as	   findings	   of	   131-­‐I	   Rx	   WBS	   were	   recorded.	   131-­‐I	   Dx	   WBS	  
findings	  during	  patients	  recruitment	  were	  interpreted	  by	  a	  nuclear	  medicine	  specialist	  
and	  grouped	  into	  two	  groups:	  complete	  structural	  response	  or	  structural	  evidence	  of	  
disease	  (SED).	  For	  patients	  with	  131-­‐I	  Dx	  WBS	  showing	  abnormal	  uptake	   in	  the	  neck,	  
high	  dose	  radioiodine	  therapy	  (RAT)	  100-­‐150	  mCi	  was	  given	  6	  months	  later,	  followed	  
by	  131-­‐I	  Rx	  WBS	  (using	  the	  same	  image	  acquisition	  protocol)	  to	  confirm	  the	  previous	  
131-­‐I	  Dx	  WBS	  findings.	  On	  the	  other	  hand,	  patients	   for	  whom	  131-­‐I	  Dx	  WBS	  showed	  
physiological	  uptake,	  another	  I-­‐131	  Dx	  WBS	  was	  performed	  6	  months	  later	  (using	  the	  
same	  image	  acquisition	  protocol)	  for	  second	  confirmation.	  	  	  
sTg	  was	   taken	   at	   two	   different	   intervals:	   6	  months	   after	   RRA	   (when	   patients	  
were	   recruited	   for	   this	   study)	  and	  12	  months	  after	  RRA.	  Serum	  anti-­‐Tg	  antibody	  and	  
TSH	  were	  taken	  together	  each	  time	  taking	  serum	  Tg.	  The	  collected	  data	  was	  analyzed	  
using	  IBM	  Statistic	  SPSS	  Version	  22.	  The	  correlation	  of	  sTg	  at	  6	  months	  post	  RRA	  with	  
SED	   in	   131-­‐I	   Dx	   WBS	   was	   determined	   using	   simple	   logistic	   regression;	   sensitivity,	  
specificity,	   negative	   predictive	   value	   and	   positive	   predictive	   value	   of	   sTg	   were	  
determined	   using	   two	   by	   two	   tables	   and	   the	   repeatability	   of	   sTg	   taken	   during	  


























	   	  




















I-131 Rx WBS: Distant metastasis,  
excluded from study, continue with  
high dose radioiodine therapy 
6 months later 
Repeat stimulated Tg 
+ High dose radioiodine therapy 
+ I-131 Rx WBS 
Repeat stimulated Tg 






Persistent uptake in the neck 
Total	  thyroidectomy	  followed	  by	  radioiodine	  remnant	  ablation	  
(RRA)	  80-­‐120	  mCi	  and	  whole	  body	  scan	  
I-131 Rx WBS: Uptake seen in the thyroid bed or neck only 
 
Recruit patients 
Take serum Tg, anti Tg Ab, serum TSH 
 
6 months later 6 months later 































4.1	   DEMOGRAPHIC	  DATA	  
Table	  2	  	   Demographic	  Data	  In	  terms	  of	  Age,	  Gender	  and	  Clinical	  Characteristics	  	  
	  	  
Table	  3	  	   Stimulated	  Tg	  and	  Diagnostic	  Whole	  Body	  Scan	  Findings	  6	  months	  after	  
	   	   Initial	  Therapy	  
	   	  
	  
	   (Notes:	  Please	  refer	  to	  Appendix	  E	  for	  details	  on	  each	  patients,	  clinical	  characteristics	  	  
	   	   and	  data	  collected).	  
	  
	  
Demographic	  Data	  and	  Clinical	  Characteristics	  
	   Number	   Percent	  (%)	  
Age	  of	  Patients	   <55	   30	   71.4	  
≥55	   12	   28.6	  
	  
Gender	  of	  Patients	   Male	   8	   19.0	  
Female	   34	   81.0	  
	  
Types	  of	  	  
Thyroid	  Cancer	  
Papillary	   33	   78.6	  
Follicular	   9	   21.4	  
	  
Tumor	  Size	  (cm)	   0.1-­‐1.0	   6	   14.3	  
1.1-­‐2.0	   16	   38.0	  
2.1-­‐4.0	   15	   35.7	  
≥4.1	   5	   11.9	  
	  
Cervical	  Lymph	  Nodes	  	  
Metastasis	  
Yes	  	   10	   23.8	  
No	   32	   76.2	  
Summary	  of	  Collected	  Data	  
Stimulated	  Thyroglobulin	  	  
6	  months	  after	  radioiodine	  	  
remnant	  ablation	  (RRA)	  
<1.0	   20	   47.6	  
1.0	  -­‐	  <2.0	   1	   2.4	  
2.0	  -­‐	  <10.0	   9	   21.4	  
≥	  10.0	   12	   28.5	  
	   	   	  
Diagnostic	  whole	  body	  scan	  
6	  months	  after	  RRA	  
SED	  in	  Neck	   9	   21.4	  






Table	  4	  	  	   Stimulated	  Thyroglobulin	  (sTg)	  in	  Patients	  With	  and	  Without	  Structural	  	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  Evidence	  of	  Disease	  (SED)	  in	  Diagnostic	  Whole	  Body	  Scan	  (I-­‐131	  Dx	  WBS)	  
	  
Persistent	  SED	  in	  	  
I-­‐131	  Dx	  WBS	  in	  the	  neck	  
Number	  of	  Patients	   Mean	  sTg	  (ug/L)	  
Yes	   9	   180.5	  
No	   33	   14.8	  
	  
	  
4.2	   STIMULATED	  THYROGLOBULIN	  TO	  PREDICT	  STRUCTURAL	  DISEASE	  
	  
Correlation	  of	  sTg	  and	  SED	  in	  I-­‐131	  WBS	  
	   Correlation	   between	   stimulated	   thyroglobulin	   6	   months	   after	   radioiodine	  
remnant	   ablation	   and	   structural	   evidence	   of	   disease	   in	   I-­‐131	  WBS	   was	   determined	  
using	  simple	  logistic	  regression	  SPSS:	  
	  	  	  Table	  5	  	   The	  correlation	  of	  sTg	  at	  6	  Months	  Post	  RRA	  with	  SED	  in	  131-­‐I	  Dx	  WBS.	  
	  







B	   Std.	  Error	   Beta	   	  
1	  (Constant)	   .136	   .060	   	   2.276	   .028	  
TG6	   .003	   .001	   .511	   3.756	   .001	  
	  
Simple	  logistic	  regression	  revealed	  significant	  correlation	  of	  sTg	  6	  months	  after	  
RRA	   with	   SED	   in	   131-­‐I	   Dx	   WBS	   (p<0.05).	   This	   also	   implied	   the	   odd	   of	   having	   SED	  
increased	  with	   every	  unit	   of	   increased	   in	   sTg.	   Subsequent	   analysis	   of	   the	   sensitivity,	  
specificity,	   negative	   Predictive	   Value	   and	   Positive	   Predictive	   Value	   of	   sTg	   6	   months	  
after	  RRA	  for	  SED	  in	  I-­‐131	  Dx	  WBS	  was	  determined	  using	  two	  by	  two	  table	  
